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ABSTRACT
Introduction: Verrucae are extremely common, and are
experienced by most people at some time during their
lives. Although most verrucae will spontaneously
disappear without treatment, many patients seek
treatment, often because they have persisted for many
years, are unsightly or painful or prevent them from
doing sports or other activities. There are many different
treatments available; including the Falknor’s needling
procedure. To date, there has only been one small trial
evaluating the clinical effectiveness of this treatment and
no health economic analysis has been undertaken. The
Effective Verruca Treatments (EVerT2) trial aims to
evaluate the clinical and cost-effectiveness of the
needling procedure for the treatment of verrucae.
Methods and analysis: This single-centre
randomised controlled trial will recruit 58 participants
(aged 18 years and over with a plantar verruca) from
Salford Podiatry Clinic patient lists and the surrounding
area. If the participant presents with multiple verrucae,
an ‘index’ verruca (largest and thickest lesion) will be
identified and patients will be randomised 1:1 to the
intervention group to receive the needling treatment or
the control group to have the callus overlying the
verruca debrided. The primary outcome is complete
clearance of the index verruca at 12 weeks after
randomisation. Secondary outcomes include clearance
and recurrence of the treated verruca, clearance of all
verrucae, number of verrucae remaining, change in size
of the index verruca, pain, and participant satisfaction. A
cost-effectiveness analysis of the needling versus callus
debridement will be carried out from the perspective of
health services over a time horizon of 12 weeks.
Ethics and dissemination: Ethical approval has been
obtained from the University of Salford, Department of
Health Sciences Ethical Approval Committee (HSCR15/
24) and the University of York, Department of Health
Sciences Research Governance Committee (HSRGC/
2014/98/B). Findings will be disseminated through
publication and conference presentations.
Trial registration number: ISRCTN16429440.
INTRODUCTION
Verrucae (or plantar warts) are caused by
the human papilloma virus.1 They are
common, and can present in people of all
ages. Population-based studies estimating the
prevalence rates of verrucae have produced
varying results, ranging from 0.84% (USA),2
to 3.3% (UK),3 and up to 12.9% (Russia).4
Verrucae can be asymptomatic, unsightly,
painful and debilitating. Although some ver-
rucae will spontaneously disappear without
treatment,5 some verrucae remain for many
years, motivating patients to seek treatment.
The rate of natural clearance of warts from
initial infection is not clear. Early research by
Massing and Epstein5 suggests that there is a
greater chance of clearance within the ﬁrst
2 years of infection. However, clearance rates
reported in the placebo arms of trials suggest
that clearance may take place sooner than
this. A Cochrane systematic review of wart
treatments reviewed 21 trials with placebo
groups,6 and found a clearance that averaged
27% (range 0–73%) in the placebo groups
after an average period of 15 weeks (range
4–24 weeks). These data have led some prac-
titioners to recommend that warts should not
Strengths and limitations of this study
▪ The design of the trial is robust. The randomisa-
tion process and concealment of allocation are
adequate, with blinded primary outcome
assessment.
▪ This study is a single-centre study in a
University Podiatry clinic and the intervention
will be delivered by up to two podiatrists.
Although this ensures standardisation of the
intervention protocol, the results may not be
generalisable to other settings or to patients with
other types of cutaneous warts.
▪ The trial is powered to show a clinically mean-
ingful difference in clearance rates of verrucae of
40 percentage points (from 30% in the control
group to 70% in the intervention group) at 12
weeks after randomisation.
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be treated at all.1 7 However, there is no reliable means
of predicting which warts will clear spontaneously and
which will remain for years.
The Cochrane systematic review assessed the effect-
iveness of different local treatments of cutaneous non-
genital warts.8 The report highlighted the consider-
able uncertainty around the optimal treatment of ver-
rucae. In 1969, Falknor9 described a needling
technique for the treatment of verrucae. The tech-
nique involves administering a local anaesthetic to the
region where the verruca is present. A needle is then
inserted into the verruca until it exits the verruca
tissue and enters the underlying dermis and subcuta-
neous fat layer. Once the boundary between the
verruca capsule and the underlying fat is pierced, the
needle is removed and the same process is repeated in
an area of tissue immediately adjacent to the previous
puncture until the entire surface of the verruca has
been punctured. It is hypothesised that the mechan-
ical trauma to the viral tissue may enhance the inﬂam-
matory response and hence the immune response
within the area.10 In a retrospective review of 45
patients who underwent the needling procedure, 31
(69%) cases demonstrated complete clearance of ver-
rucae, 3 (7%) demonstrated a reduction in size and
pain and 11 showed no improvement 8 weeks after
treatment. No adverse events were reported from any
of the patients.11 To date, we are aware of only one
trial evaluating the effectiveness of this needling pro-
cedure.12 This was a small trial involving 37 partici-
pants, randomised to receive either the needling
technique or cryotherapy. Results of this study showed
a statistically signiﬁcant difference in the clearance of
the primary pedal wart in the needling group of
64.7% (11/17) compared with 6.2% (1/16) in the
cryotherapy group (p=0 .001) 12 weeks after the initial
treatment. Unlike the retrospective study,11 this study
involved delivering the treatment up to three times at
least 2 weeks apart. There was no signiﬁcant difference
in pain or satisfaction with treatment between the two
groups.
OBJECTIVE
The objective of the EVerT2 (Effective Verruca
Treatments) trial is to evaluate the clinical and cost-
effectiveness of the needling procedure compared with
callus debridement for the treatment of verrucae. The
null hypothesis is that there is no difference in the clear-
ance rates of the index verruca as assessed by a blinded
independent assessor at 12 weeks postrandomisation
between the two treatment groups.
EVerT2 is the second randomised controlled trial
(RCT) conducted in collaboration with the York Trials
Unit (YTU) at the University of York, focusing on the
treatment of verrucae. The ﬁrst trial (EVerT) tested the
efﬁcacy of salicylic acid and cryotherapy treatments for
verrucae.13
METHODS AND ANALYSIS
Trial design
This will be a single-centre, pragmatic, open, two-arm
RCT with an economic evaluation. Participants with ver-
rucae will be randomised 1:1 to receive the needling
procedure or to callus debridement. Participant progress
through the study is shown in ﬁgure 1.
Setting and participants
The trial will be conducted in the Podiatry Clinic at the
School of Health and Social Care, University of Salford,
UK. Data management and statistical analysis will take
place at the YTU, University of York, UK.
Recruitment
The podiatry clinic at the University of Salford is a
private, teaching clinic. A self-referral system is in place
for all patients. Potential participants for the trial will be
identiﬁed by a qualiﬁed podiatrist, registered with the
Health Care Professions Council (HCPC; UK) at the
study site. In order to facilitate recruitment the following
strategies will be used:
▸ The podiatry clinic has a range of patients in the
system with verrucae. These participants will be
viewed on the computer system and those deemed to
be suitable (ie, ﬁt and healthy, and aged 18 or over)
will be sent a letter advertising the study and asking
them to contact the investigators if they are interested
in participating.
▸ Flyers will be distributed within the University, includ-
ing the podiatry clinics, the Student’s Union, the
leisure centre and University campus buildings.
▸ Recruitment ﬂyers will also be distributed in local
community areas accessed by the general public
including supermarkets, health centres, day centres,
leisure centres and athletics clubs.
▸ Radio and/or newspaper advertisements will be used
to give a brief description of the project and invite
individuals that are interested in taking part to phone
or email for further details.
▸ Adverts may be placed on the University of Salford’s
Twitter feeds; other twitter or other social media
accounts used for professional scientiﬁc purposes; or
other electronic noticeboards within the University of
Salford.
Potential participants will be sent an invitation letter,
information sheet about the trial and a baseline ques-
tionnaire and will be provided with an appointment for
assessment/treatment. For individuals responding to an
advert for trial participants, telephone screening by the
study site will be undertaken to ensure that the potential
participants fulﬁl the inclusion criteria. Participants will
be given a minimum of 24 h to read the information
sheet and consider participation. At the baseline
appointment, the podiatrist will ensure that the patient
is eligible for the trial, take consent, check that all base-
line data have been completed and randomise the
patient. The patient will then receive the allocated
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treatment at the same appointment. Participants’
general practitioners (GPs) will be notiﬁed of their
involvement in the trial after recruitment.
Inclusion criteria
Potential participants will be eligible if they have a
plantar verruca that, in the opinion of the podiatrist, is
suitable for both treatments: scalpel debridement and
needling. The clinical diagnosis of a verruca will be
made by a qualiﬁed podiatrist, registered with the HCPC
(UK), observing the following criteria: ﬂesh coloured,
hyperkeratotic lesion with discrete margins and a papil-
lomatous surface. The skin striae will be either broken
or diverge around the lesion. Some verrucae may
contain black dots of thrombosed capillaries. The
lesions are often painful when pinched. Verrucae on
weight bearing skin sites only will be included. All parti-
cipants will be aged 18 years and older.
Exclusion criteria
Potential participants will be excluded if, in the opinion
of the podiatrist, they are not suitable for local anaesthe-
sia. Local anaesthesia is an absolute contraindication in
potential participants who have a history of type 1 hyper-
sensitivity reaction to local anaesthesia; who have infec-
tion or poor tissue viability at the site of injection; who
Figure 1 Flow chart of participants through the trail (YTU, York Trials Unit).
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do not consent (refusal) or when there is non-
cooperation on the participant’s behalf (this includes
the patient moving the foot when attempting to inject
or any other circumstance when the patients actions put
themselves or the practitioner at risk of needle stick
injury). Relative contraindications include participants:
in the ﬁrst trimester of pregnancy; with compromised
renal and hepatic function; with cardiorespiratory pro-
blems such as angina and myocardial infarction; who
are elderly or debilitated patient; with marked periph-
eral neuropathy; with progressive neurological disease;
with epilepsy still suffering seizures.
Exclusion will also apply if the potential participants:
have impaired healing (eg, due to diabetes, peripheral
vascular disease or any other condition); are immuno-
suppressed (or are currently taking immunosuppressant
drugs such as oral corticosteroids); have peripheral
neuropathy; are currently on renal dialysis; are pregnant;
are unable or unwilling to give informed consent; or are
currently in a trial evaluating other treatments for their
verruca(e).
Sample size estimation
With regard to the efﬁcacy of the needling procedure, a
retrospective review of 45 patients who underwent this
procedure found that 69% cases demonstrated complete
clearance of the verrucae 8 weeks after treatment.11 A
recent RCT compared the efﬁcacy of two verrucae treat-
ments (needling procedure and cryotherapy with liquid
nitrogen).12 This study found a 65% clearance rate of
the index verruca among the participants allocated to
the needling procedure compared with 6% among
those treated with cryotherapy after 12 weeks of
follow-up.
The EVerT2 trial is powered to show a more conserva-
tive but still clinically meaningful difference in clearance
rates of the index verruca of 40 percentage points (from
30% in the control group to 70% in the intervention
group) at 12 weeks after randomisation. A Cochrane sys-
tematic review of wart treatments found that the placebo
arms of 21 trials had an average clearance rate of 27%
after an average period of 15 weeks; hence, a control
rate of 30% was chosen. In addition, powering to detect
a difference from 70% to 30% requires the largest
sample size to detect a 40 percentage point difference.
For 80% power (5% two-sided signiﬁcance), 26 partici-
pants per group are required. Allowing for 10% attri-
tion, we will require 58 participants to be recruited and
randomised (29 into each treatment group).
Randomisation
The random allocation sequence will be generated by
the trial statistician using block randomisation with ran-
domly permuted block sizes. Allocations will be con-
cealed in sequentially numbered, opaque, sealed
envelopes kept at the YTU. The allocations will be con-
cealed from the podiatrists enrolling the participants to
the study. Once a patient is ready to be randomised, the
podiatrist recruiting the patient will ring the secure ran-
domisation telephone number at the YTU for the treat-
ment allocation.
INTERVENTIONS
Intervention group: needling procedure delivered by a
HCPC registered podiatrist
If the participant presents with mosaic verrucae or mul-
tiple plantar warts, the index verruca (the largest and
thickest lesion) will be selected for treatment. The area
surrounding the lesion will ﬁrst be cleansed with skin
disinfectant. A local anaesthetic (Scandonest 3%) will be
administered via tibial nerve block, digital block or local
inﬁltration according to the location of the lesion
chosen for needling. Once the area of skin is anaesthe-
tised, any callus overlying the verrucae will be debrided.
An empty surgical needle (21 gauge) will be used to
repeatedly puncture through the lesion to the subcuta-
neous tissue. Each puncture will produce point bleeding
and this will be continued until there is no more resist-
ance, or reactive pressure, from the epidermis and the
entire lesion has perforated enough to produce a ‘beefy’
red wound. The total number of punctures will vary
according to the size of the lesion.
Pressure will then be applied to the wound with a
sterile gauze. The wound will be dressed with a non-
adherent sterile dressing (Melolin) and ﬁxing tape
(Meﬁx). A semicompressed felt aperture pad will also be
applied to deﬂect pressure when walking and reduce
postoperative bruising. Each participant will be issued
with a postoperative care leaﬂet and advised to lightly
shower and wash the area after keeping the dressing and
padding dry for 24 h after treatment. Each participant
will be advised to avoid taking non-steroidal anti-
inﬂammatory drugs (such as ibuprofen) or other anti-
inﬂammatory medication for 48 h to increase the likeli-
hood of a successful controlled inﬂammatory response.
Patients will be permitted to take paracetamol if they
require pain relief.
This intervention will be delivered on one occasion
only. Patients will attend a review appointment 1 week
after the treatment where wound inspection and
debridement of any uncomfortable eschar will be per-
formed, and 12 weeks after randomisation for primary
outcome data collection. At the 12-week appointment
overlying callus will be debrided if the lesion is causing
discomfort to the participant. Details of any treatment
or advice given will be recorded on a podiatrist question-
naire. The ﬁnal inspection for verrucae clearance will be
carried out at 24 weeks postrandomisation. If the
verruca has not cleared at this stage then further, alter-
native treatments may be offered.
Control group: debridement of callus overlying verruca
delivered by a HCPC registered podiatrist
The area surrounding the lesion will ﬁrst be cleansed
with skin disinfectant. The callus overlying the verrucae
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will be removed using a surgical blade. This procedure is
common practice for the removal of plantar callus. If
the participant presents with mosaic verruca or multiple
plantar warts, then all verruca callus will be debrided if
the participant requests this and the podiatrist considers
that it is safe to do so. However, the index verruca will
be selected on which to assess outcome measures.
Post-treatment, a semicompressed felt aperture pad will
be applied to deﬂect pressure when walking and reduce
postoperative bruising. Each participant will be advised
to lightly shower and wash the area after keeping the
dressing and padding dry for 24 h after treatment.
Patients will attend a review appointment 12 weeks after
randomisation for primary outcome data collection. If
the patient is experiencing pain or discomfort due to
the callus, then the callus overlying the verruca(e) will
be further debrided. Details of any treatment or advice
given will be recorded on a podiatrist questionnaire.
The ﬁnal inspection for verrucae clearance will be
carried out at 24 weeks postrandomisation. If the
verruca has not cleared at this stage, then further alter-
native treatments may be offered, which may include the
needling procedure.
A ‘no treatment’ arm will not be included in this
study. It is likely that people will volunteer for this study
to access the novel treatment needling procedure which
is not widely available either at the National Health
Service (NHS) or private podiatry clinics. The risk of
losing participants to follow-up would be high if these
participants are randomised into a ‘no treatment’
group. Therefore, offering callus debridement, which is
currently the mainstay of treatment in some NHS podia-
try clinics, may help to maximise participant retention
throughout the trial, particularly with the offer of free
needling treatment at the end of the trial if their verru-
cae persist. Second, a ‘no treatment’ arm may lead to
bias due to resentful demoralisation, particularly in
those participants where the verrucae are painful, long
standing and have been resistant to previous treatment.
The use of a ‘sham’ needling treatment for the control
group was considered; however, the trial team concluded
that it would be unethical to administer a local anaes-
thetic if no treatment is to be given.
All treatments will be conducted by up to two podia-
trists proﬁcient in the needling procedure. In order to
standardise understanding and implementation of study
procedures, the podiatrists will review the following
documentation together prior to the start of study: back-
ground and aims of the trial; inclusion/exclusion cri-
teria; the randomisation process; protocols for both
treatments; documentation/forms used in the trial, for
example, randomisation forms, questionnaires, adverse
event reporting; and possible ‘Frequently asked ques-
tions’ participants may ask about the trial.
All participants will receive a high street shopping
voucher for the sum of £20 in recognition of their par-
ticipation in the study and to offset any incidental
expenses associated with completing the questionnaires
and attending clinics. This money will be split between
the 12-week and 24-week follow-up appointments.
OUTCOME MEASURES
Baseline assessment
After written informed consent has been obtained,
baseline data will be collected using a baseline question-
naire. The following data will be collected: participant
gender and date of birth; the type (plantar calcaneus,
plantar MTPJ, mosaic or other) and number of verruca
(e); size of the index verruca; the length of time the
participant has had the verruca(e); previous treatment
for current verruca(e); reason for seeking treatment;
level of pain; number of previous verrucae; and age of
last verruca.
Primary outcome
The primary outcome will be complete clearance of the
index verruca at 12 weeks after randomisation as deter-
mined by blinded assessment by a HCPC registered
podiatrist working at the clinical site. ‘Clearance’ of
verruca will be deﬁned as the restoration of normal skin
on close inspection, with the return of normal dermato-
glyphics to the treated area of skin, that is,
uninterrupted skin striae as assessed by the podiatrist.
The blinded outcome assessment will be undertaken by
a member of the research team who is unaware of the
treatment the participant has received. The assessor will
record whether or not the verruca has completely
cleared on the podiatrist outcome assessment form.
Participants will be reminded not to tell the person
undertaking the blinded assessment which treatment
they received.
Participants who do not attend their 12-week appoint-
ment will be contacted and asked to email a digital
photograph of their verruca to the podiatry clinic email
account with their participant ID number and the date
the photo was taken.
Secondary outcomes
The secondary outcomes will be: pain 24 h after the
treatment, clearance or recurrence of the treated
verruca at 24 weeks, clearance of all verrucae, number
of verrucae remaining, change in size of the index
verruca, pain, and participant satisfaction at 12 and
24 weeks.
Data on self-reported clearance of verrucae, self-
reported time to clearance, recurrence of verrucae at
24 weeks, satisfaction with treatment and pain levels will
be recorded using patient questionnaires. Data on the
number of treatments, number of verrucae remaining at
12 and 24 weeks, and change in size of verrucae at 12
and 24 weeks will be recorded by the treating podiatrist
using a podiatrist questionnaire.
In addition to this, side effects of treatment, pain
intensity after treatment and use of painkillers will be
recorded and assessed by a participant questionnaire,
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which will be given to the participant after their ﬁrst
treatment. The participant will be asked to complete and
send this questionnaire back to the YTU 1 day after their
treatment, in the prepaid envelope provided.
Participants will be given a ‘verruca gone’ form and
stamped address envelope at their ﬁrst treatment session,
which the participant will complete and send back to the
YTU when they assess their verrucae have gone.
Table 1 contains details of the outcomes that will be
measured throughout the trial. The majority of the out-
comes are responses to questions that require a ‘yes’ or
‘no’ answer or open comments, apart from measure-
ments of verruca size; pain and satisfaction measures.
Verruca size measurements will be taken from digital
photographs using ImageJ software (V.1.49p, National
Institute of Health, USA, http://imagej.nih.gov/ij, Java
V.1.6.0_24 (32 bit)). A standard protocol will be used for
all photographs, as follows. The participant trial ID card
will be placed directly under the verruca, so that the
scale is perpendicular to the base of the verruca. All
attempts will be made to ensure that the ID card is not
at an angle to the base of the verruca and is ﬁrmly
adhered to the foot. A white card will be placed behind
the foot before taking the photograph. Each photo-
graph will be taken at a distance of 10 cm away from the
foot. This is a sufﬁcient distance to ensure that the
verruca and the ID card are in the picture frame. All
attempts will be made to ensure that the camera is not
at an angle to the bottom of the foot. The ﬂash facility
will not be used as the research room has sufﬁcient
Table 1 Details of outcome measures and data collection forms
Measure
Source (form/questionnaire)
Content
Eligibility Eligibility form Consent criteria: patient provided informed written consent to entering the
trial (Y/N)
Inclusion criteria: aged 18 years or over; presence of a verruca that can be treated with
both needling and callus debridement (all Y/N).
Exclusion criteria: impaired healing; participation in another trial for the treatment of
verrucae; immunosuppressed or currently taking immunosuppressant drugs; currently on
renal dialysis; peripheral neuropathy; pregnancy; unsuitable for local anaesthesia (all Y/N)
General demographic details Baseline questionnaire
Date of birth; sex (male, female)
History of treatment details;
number and type of verrucae
Eligibility form
Type of verruca (plantar calcaneus, plantar metatarsal, mosaic, other); number of
verrucae
Baseline questionnaire
Age of index verruca (months and weeks); previous treatments used (self-treatment,
podiatrist or GP treatment, participation in a verruca trial, other) with details; reasons for
seeking treatment (pain, inhibition of swimming and/or sports activities, other); previous
verrucae (number of previous verruca and age at last verruca)
Satisfaction with treatment; use
of pain killers; restriction to
lifestyle; side effects of treatment
Participant questionnaires
1-day follow-up questionnaire
Use of painkillers (Y/N); any comments (free text).
12-week and 24-week follow-up questionnaires
Participant opinion on verrucae clearance (Y/N); if cleared, date of clearance; comments
on any problems associated with treatment (free text); willingness to have same treatment
in the future (yes, no, not sure); satisfaction with treatment (5-point Likert scale)
Pain scores (VAS: 100 mm scale
0=no pain—100 worst possible
pain)
1-day follow-up questionnaire
12-week and 24-week follow-up questionnaires
Size (mm2) Eligibility form
12-week and 24-week follow-up questionnaires
Podiatrist blinded outcome assessment form
Podiatrist outcome assessment Podiatrist outcome assessment form at 12 and 24 weeks
Complete clearance of index verruca (Y/N); number of verrucae remaining; need for
further treatment (Y/N with details of treatment provided); blinded podiatrist’s opinion on
trial treatment received by participant(needling, debridement, unable to tell); any
comments (free text)
Healthcare resource utilisation 12-week and 24-week follow-up questionnaires
Number and dates of visits to the research clinic; number and dates of visits to other
practitioners (GP/nurse) during trial period; purchase of other treatments during trial, with
costs
GP, general practitioner; N, no; VAS, visual analogue scale; Y, yes.
6 Hashmi F, et al. BMJ Open 2015;5:e009406. doi:10.1136/bmjopen-2015-009406
Open Access
group.bmj.com on November 25, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
lighting. The zoom facility will not be used, that is, after
turning on the camera the zoom will not be adjusted.
The image will be opened in the ImageJ software
package and the area of the lesion will be measured
three times and the mean value used as the outcome
measure. These measurements will be taken by a
researcher who is blinded to the intervention. Pain will
be measured using a 100 mm visual analogue scale.
Participant satisfaction will involve asking the following
question ‘How happy are you with your treatment?’ and
recording the response using the following Likert scale:
very unhappy, unhappy, neither happy nor unhappy,
happy or very happy.
Adverse events
The podiatrist will routinely record and report any
serious adverse event (SAE) and non-SAE/reactions,
which are directly related to the trial treatments or
related to being in the study, which occur during the
course of the trial. Any adverse events deemed not
related to the trial treatment or related to being in the
study will not be recorded or reported.
An adverse event is deﬁned as any untoward medical
occurrence which has occurred in a patient taking part
in the study. A SAE is deﬁned as any untoward occur-
rence that: results in death; is life threatening; requires
hospitalisation or prolongation of existing hospitalisa-
tion; results in persistent or signiﬁcant disability or
incapacity; consists of a congenital anomaly or birth
defect or is otherwise considered medically signiﬁcant
by the investigator.
Adverse events will be recorded on an adverse event
form, as appropriate. An assessment of the seriousness,
causality, expectedness and intensity of the event/reac-
tion will be undertaken. Participants will be asked at
each trial visit whether they have had any problems fol-
lowing their treatment and if any adverse events have
occurred. The adverse event reaction reporting period
for this trial begins when the participant is randomised
into the study and ends 24 weeks after the date of ran-
domisation. All recorded and reported adverse events
and reactions will be followed up until they are resolved
or the participant’s participation in the trial ends. In
addition, serious adverse reactions assessed by the inves-
tigator as being possibly related to the investigational
procedure will continue to be followed even after the
participant’s participation in the trial is over. Such reac-
tions will be followed until they resolve or until the inves-
tigator assesses them as ‘chronic’ or ‘stable’. Appropriate
ongoing care will be arranged through the appropriate
services. Resolution of such events will be documented
on the adverse event form.
Potential complications associated with the needling
procedure and callus debridement are: pain, irritation,
infection, bleeding for longer than clinically expected
following the needling procedure and scarring. In very
rare cases patients may fall as a result of the
treatment.
DATA HANDLING
Transfer of data and data entry
Data shall be collected via paper questionnaires.
Where data collection is conducted at the University of
Salford, completed paper questionnaires will be
scanned and electronic copies will be sent to the YTU,
University of York, via the University of York’s secure,
ﬁle exchange DropOff service. Wherever possible, iden-
tiﬁable details on any correspondence or records will
be removed and replaced with the participant’s unique
trial ID number. The YTU will not hold personal
details of participants or consent forms. In cases where
participants are asked to complete a questionnaire at
home, a stamped addressed envelope for the YTU will
be supplied.
Data from participant and podiatrist questionnaires
returned to the YTU will be manually entered into
bespoke databases, housed on the YTU secure server.
The YTU has a backup procedure approved by auditors
for disaster recovery. YTU-based standard operating pro-
cedures will be used for entering and checking data.
Data quality checks will be undertaken to ensure the
accuracy of the data. Any data queries will be raised with
the site.
Data storage
All data will be treated with the strictest conﬁdence and
in accordance with the Data Protection Act 1998. Paper
study documents will be retained in a secure (locked
when not in use) cabinet in a locked room both during
and after the trial has ﬁnished. During the course of the
trial any personal identiﬁable paper records will be
stored separately from anonymised paper records. Once
the study is complete, data will be temporarily held in
the department archive before being sent to the
University of Salford for archiving. Data will be put in
sealed boxes. Access to the archive is restricted and is via
the named archivist. Access will only be allowed if a data
query arises which requires access to the data in order to
resolve the issue. All electronic records will be stored on
a secure, password protected server within the YTU
indeﬁnitely.
STATISTICAL ANALYSIS
There will be a single analysis at the end of the study
using two-sided signiﬁcance tests at the 5% signiﬁcance
level for the primary outcome measure and 1% signiﬁ-
cance level for secondary outcome measures. We will use
‘intention-to-treat’ analysis including all participants in
the groups to which they were randomised irrespective
of whether or not they received their allocated treat-
ment. Analysis will be conducted in Stata V.13 or later
(StataCorp LP, College Station, Texas, USA). Results will
be reported according to CONSORT guidelines and a
ﬂow diagram depicting the progression of patients
through the trial will be presented.
Hashmi F, et al. BMJ Open 2015;5:e009406. doi:10.1136/bmjopen-2015-009406 7
Open Access
group.bmj.com on November 25, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
Trial completion and baseline data
Participants will have the option, at any time, of with-
drawing from the trial treatment; withdrawing from com-
pleting postal questionnaires; and withdrawing from the
collection of data by the podiatrist. If the participant
elects to withdraw from all three, then he or she will be
deemed as a full withdrawal. Healthcare professionals
are able to indicate any change in the patient’s level of
participation by completing a change of circumstances
form. The numbers of participants withdrawing from
treatment and/or the trial will be summarised with the
reasons where available.
Participants will be deemed to exit the trial when: the
participant has been in the trial for 24 weeks; the partici-
pant wishes to withdraw from the trial fully; the partici-
pant’s healthcare professional withdraws him/her from
the trial; the participant is lost to follow-up; or the par-
ticipant dies.
Baseline data
All data collected at baseline such as gender, age, type
and duration of verrucae and previous treatments will
be summarised. Continuous variables will be reported
using descriptive statistics (eg, mean and SD), and
for categorical data we will report numbers and
percentages.
Primary analysis
The primary outcome is complete clearance of the
index verruca at 12 weeks, which will be a dichotomous
outcome (presence or absence of verruca). The propor-
tions of participants with complete clearance of the
index verruca will be compared using a χ2 test.
Secondary analysis
A logistic regression model will be used to adjust the
primary analysis for three important prognostic variables
(age, whether or not the verrucae have been previously
treated and type of verruca). ORs and corresponding
95% CIs will be provided.
Complete clearance of all verrucae at 12 and 24 weeks
as determined by a blinded assessor, participant self-
reported clearance of verrucae at 12 and 24 weeks, and
recurrence of verrucae at 24 weeks will be analysed in
the same way as the primary outcome.
At 12 and 24 weeks, an assessment of whether the ver-
rucae have cleared will be made by both the participant
and the blinded assessor. The Cohen’s κ measure of
inter-rater agreement will be used to assess the agree-
ment between the two assessments at each time point.
Poisson, or negative binomial, regression as appropri-
ate will be used to compare the number of verrucae at
12 and 24 weeks between the two treatment groups, with
adjustment for the number of verrucae at baseline.
Self-reported time to clearance of all verrucae in days
from randomisation will be analysed using a Cox propor-
tional hazards model adjusting for age, whether or not
the verrucae have been previously treated and type of
verruca. Participants will be right censored if they are
lost to follow-up or if their verrucae have not cleared, as
appropriate.
Data on side effects of treatment, pain intensity after
treatment, use of painkillers, treatment details and par-
ticipant satisfaction with treatment will be summarised
and descriptive statistics provided.
Missing data
The amount of missing baseline data should be
minimal as this will be checked by the podiatrist at the
ﬁrst appointment prior to the participant being rando-
mised. We will try and minimise any missing data with
respect to the primary outcome of index verruca clear-
ance within 12 weeks. However, if we are unable to
ascertain the status of any patients, then they will be
treated as not having a cleared verruca in the primary
analysis.
Health economics
The primary approach to economic evaluation will be a
cost-effectiveness analysis of the trial intervention (need-
ling) versus usual care (debridement). The evaluation
will be carried out from the perspective of health ser-
vices, over a time horizon of 12 weeks.
Costs associated with resource use will be calculated
for each trial participant using data collected from the
self-report questionnaires given to participants at
12 weeks. Resource use data will be collected in terms of
number of visits to the podiatrist or other healthcare
professionals for wart-related treatments. Costings will be
applied using standardised costs where available, for
instance, visits to NHS staff such as GPs or nurses will be
costed according to standard NHS costs.14 Costs of deli-
vering the intervention will be calculated from the trial
and will use standardised costs where available, for
example, for the podiatrists’ time.
The primary patient outcome for the economic ana-
lysis will be the primary trial outcome; complete clear-
ance of the index verruca at 12 weeks. The incremental
mean difference in costs between the two trial arms and
incremental difference in patient outcome will be calcu-
lated to provide an incremental cost-effectiveness ratio
(ICER) of cost per patient cured at 12 weeks. This will
result in one of four scenarios:
1. Needling is less costly than debridement and leads to
better patient outcomes;
2. Needling is more costly than debridement and has
worse outcomes;
3. Needling is more costly than debridement but has
better patient outcomes;
4. Needling is less costly than debridement and leads to
worse patient outcomes.
If the results show scenario 1 or 2, then one treatment
clearly dominates the other and there is a clear choice
about the treatment that is cost-effective. If non-
dominance occurs, as in scenarios 2 and 4, consider-
ation must be given to the potential cost implications
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versus patient beneﬁt to make a decision regarding cost-
effectiveness. This will involve relating the incremental
mean costs between the two trial arms to the incremen-
tal mean outcome as a ratio, the ICER.15 The ICER
represents the additional cost per additional patient
cured. Uncertainty regarding the cost-effectiveness ana-
lysis will be assessed using cost-effectiveness acceptability
curves
TRIAL ORGANISATION AND MONITORING
Owing to the low risk of this study, site monitoring visits
for this study will not be undertaken on behalf of the
sponsors. The study will be run using the University of
York Standard Operating Procedure Guidelines for clin-
ical trials.
With the agreement of the sponsors, one independent
steering and monitoring committee will be set up to
undertake the roles traditionally undertaken by the Trial
Steering Committee (TSC) and Data Monitoring and
Ethics Committee (DMEC). This committee will com-
prise an independent chair who will be a clinician with
expertise in podiatry, a HCPC registered podiatrist, the
chief investigator and other study collaborators. The role
of this committee will include the review of all SAEs
which are thought to be treatment related and unex-
pected. The committee will meet at least annually or
more often as appropriate. A Trial Management Group
will be formed consisting of the chief investigator; trial
coordinator; statistician; and the principal investigators
at the site. Regular meetings will be held according to
the needs of the trial.
ETHICS AND DISSEMINATION
Ethics
Participation in the study will be entirely voluntary.
Potential participants will receive written information
about the study which will include information about
the potential beneﬁts and risks of being involved in the
trial. Potential participants will have the opportunity to
discuss the information and the study with a podiatrist
who is part of the research team. If a podiatrist feels that
the potential participant is unable to give informed
consent, then they would not be eligible to take part in
the study. All participants will give written informed
consent prior to entry into the study. The podiatrist will
inform the participant if new information comes to light
that may affect the participant’s willingness to participate
in the trial.
Dissemination
Outcomes will be disseminated through publication
according to the CONSORT guidelines. This study
protocol and results from the main trial will form the
basis of academic papers. Results will be presented at
international scientiﬁc conferences. Participants will be
offered the opportunity to obtain a summary of the ﬁnd-
ings on completion of the study.
CONCLUSION
This will be the ﬁrst appropriately statistically powered
RCT to compare the clinical effectiveness of needling
for the treatment of verrucae. The study results will
provide valuable information about the impact of this
procedure on the resolution of verrucae and therefore
inform patients and healthcare practitioners of its efﬁ-
cacy. The secondary analysis at week 24 will provide evi-
dence of long-term verruca clearance or reoccurrence
in response to treatment.
TRIAL STATUS
Recruitment and follow-up are in progress. Recruitment
to the study began in March 2015 and will continue
until approximately March 2016. Follow-up will be com-
pleted in September 2016 and analysis will be conducted
between October and November 2016.
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